Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Philogen SpA ( (IT:PHIL) ) has shared an announcement.
Philogen S.p.A. announced the purchase of 6,120 of its own shares as part of its ongoing share buyback program, approved by the Board of Directors in December 2024. This transaction, conducted on the Euronext Milan market, represents 0.0151% of the company’s share capital. Since the start of the buyback program, Philogen has acquired a total of 55,776 shares, equivalent to 0.1373% of its share capital, reflecting a strategic move to consolidate its market position and potentially enhance shareholder value.
More about Philogen SpA
Philogen S.p.A. is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating diseases with high mortality rates. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through its proprietary technologies and extensive experience in drug production and development.
YTD Price Performance: 2.37%
Average Trading Volume: 228
Technical Sentiment Signal: Strong Sell
Current Market Cap: €605.3M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.